Focused On-demand Library for Transmembrane 4 L6 family member 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O14894

UPID:

T4S5_HUMAN

Alternative names:

Tetraspan transmembrane protein L6H

Alternative UPACC:

O14894; Q17RW9; Q6IB79

Background:

Transmembrane 4 L6 family member 5 (TM4SF5), also known as Tetraspan transmembrane protein L6H, plays a crucial role in cellular processes. It acts as a lysosomal membrane arginine sensor, forming a complex with MTOR and SLC38A9 to regulate arginine efflux. This process is pivotal for the activation of mTORC1, leading to the phosphorylation of RPS6KB1 and EIF4EBP1. TM4SF5 also facilitates the G1/S phase progression in the cell cycle and the nuclear translocation of the CDK4-CCND1 complex, with CDKN1B and RHOA/ROCK signaling involved in its mechanism.

Therapeutic significance:

Understanding the role of Transmembrane 4 L6 family member 5 could open doors to potential therapeutic strategies.